

Evaluation of red cell alloantibodies in thalassemia major patients referred to the blood transfusion center of Golestan province, Iran

Running title: Evaluation of red cell alloantibodies in thalassemia major patients

Seyed Sadegh Baniaghil

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Gorgan, Iran. baniaghil1344@yahoo.com
ORCID: 0000-0001-9699-991X

Fardin Balochi

Blood Transfusion Organization, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. baniaghil_sadegh@yahoo.com

Ereeste Kazak

¹ General Department of Blood Transfusion of Golestan Province, Gorgan, Iran

² Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Gorgan, Iran. ereeste.kazak@yahoo.com

Corresponding author: Seyed Sadegh Baniaghil

Email: baniaghil1344@yahoo.com

Tel: +989116434304

Address: Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Gorgan, Iran

Abstract

Background: One of the major complications in thalassemia patients is alloimmunization, which occurs when the patient produces antibodies against transfused Red Blood Cells (RBCs). In the present study, the frequency of alloantibodies in thalassemia patients was investigated.

Methods: In this cross-sectional retrospective study, the study was performed on 99 multi-transfused thalassemia patients. An antibody screening test was carried out using a three-cell panel. Positive patients were followed up for antibody identification using an 11-cell panel. The information was finally analyzed using SPSS software version 16.0.

Results: Out of ninety-nine cases, 53 were female (53.53 %) and 46 were male (46.46 %). The patient's age mean was 29.22 ± 10.46 years with 2 to 61 years' age range. Only 5.05% (N=5) had developed alloantibodies. The most common alloantibodies were Anti-D, Anti-E, Anti-c, and Anti-K. No significant correlation was seen between the presence of alloantibody and age, sex, blood type, and spleen condition.

Conclusion: Antibody production against RBC antigens is a common problem in multi-transfused thalassemia patients. Compatibility between antigens of the Kell and Rh blood group systems in donors and recipients can be one of the useful ways to prevent alloimmunization of blood recipients and the production of unexpected antibodies against the donor's red blood cells.

Key words: Alloantibody, Thalassemia, Blood transfusion

Introduction

Thalassemia is the most common genetic disorder worldwide affecting synthesis of one or more of the globin subunits of hemoglobin leading to ineffective erythropoiesis (1). Geographically, thalassemia is a Mediterranean disease and more in West Asian and Central Asian countries such as Turkey, Iran, Burma, it is found in Thailand, Vietnam and Colombia. Also, in Africa, Greece and Italy is also very common (2), it can be found in more than 60 countries with a carrier (heterozygote) population of up to 150-200 million people or 4.5% of the world population, and at least 300,000 lethally affected homozygotes are born annually (3).

In Iran, more than two million thalassemia carriers and more than twenty thousand thalassemia major patients have been identified (4). Provinces around the Persian Gulf and the Caspian Sea with a gene frequency of more than 10% constitute the thalassemia major zones in Iran (5). Patients with this haemoglobinopathy need regular transfusions. Repeated blood transfusion can stimulate the patient's immune system and results in the formation of anti-erythrocyte antibodies. This can cause a problem in the identification process of compatible blood in these patients and cause a delay in the process of supplying and injecting compatible blood (6). The possibility of creating antibodies after injecting a bag of blood is 1% to 1.6%, the reported worldwide alloimmunization frequency rate among thalassemia patients varies from 1.13% to 40.4% (7-8). Blood transfusion is the main method of treatment for these patients. However, regular blood transfusion leads to organ damage due to iron overload and immunization to RBC antigens. Iranian routine blood group typing of thalassemia patients identifies ABO and Rh (D) antigens only before blood transfusion for thalassemia patients, most of the alloantibodies are formed against them and it is the cause an increase in the need for blood transfusions, on the other hand, it makes it difficult to identify compatible blood units for subsequent blood transfusions.

Several studies have shown that, in most cases, responsible antibodies are related to the subgroups of the Rh system, including E, e, C, c and secondary groups such as Kell, Duffy, and Kidd (9-12). Blood group system antigenic difference between the donor and recipients as well as the immunomodulatory effect of the allogenic blood transfusion on the recipient's immune system are effective factors in alloimmunization. Due to receiving repeated blood in thalassemia patients from different people, the preparation of compatible blood is not easily possible for these patients. Therefore, the purpose of this study was to determine the prevalence of alloimmunization in thalassemia patients who received regular transfusions and try to avoid hemolytic transfusion reaction which may occur during future blood transfusion.

Methods

This descriptive cross-sectional study investigated alloantibodies in patients with thalassemia major receiving regular blood transfusions at the Blood Transfusion Center of Golestan Province, Iran. Demographic and clinical data, including age, gender, blood group (ABO/Rh), and spleen status, were collected from patients' medical records using a standardized checklist. For laboratory analysis, five milliliters of venous blood were collected from each patient in EDTA-containing vacutainer tubes before transfusion. Samples were centrifuged one-hour post-collection, with serum aliquoted into two tubes for antibody screening and identification. Antibody screening was performed two hours post-sampling using three screening cells (R1R1, R2R2, rr) through standard blood bank techniques, including testing phases in saline, albumin (22%), and indirect antiglobulin (Coombs) to detect RBC alloantibodies. Samples showing positive screening results underwent further analysis using 11-cell panels provided by the Immunohematology Department of Iran Blood Transfusion Organization, with confirmation through the standard tube method. All positive

results were referred to the Immunohematology Laboratory of the Blood Transfusion Organization for validation. Statistical analysis was performed using SPSS v16.0, with the chi-square test used to assess associations between variables at a 95% confidence interval, considering p-values <0.05 as statistically significant.

Results

Among 99 patients with thalassemia major receiving routine blood transfusions at 3-5 week intervals, 53% were female and 46% were male, with a mean age of 29.22 ± 10.46 years (range: 2-61). The ABO blood group distribution showed that 37% of patients were type O, 23% type B, 25% type A, and 14% type AB, while 82% were Rh(D)-positive. Alloantibodies were detected in five patients (5.05%), with the remaining 94 (94.95%) showing no evidence of alloimmunization. Of the five alloimmunized patients, three (60%) were female and two (40%) were male. Two patients (40%) developed two alloantibodies each (Anti-c and Anti-E in one case, Anti-D and Anti-K in the other), while the remaining three (60%) had single antibodies-two with Anti-E and one with Anti-D. Overall, the most common alloantibodies were Anti-E and Anti-D (each 33.3%), followed by Anti-c and Anti-K (each 16.7%). The majority of detected antibodies targeted Rh system antigens (85.7%), with Kell system antibodies accounting for the remaining 13.4%. Statistical analysis indicated no significant association ($P > 0.05$) between alloantibody formation and age, sex, blood type, or spleen status.

Discussion

Repeated blood transfusion is one form of life-saving efforts to improve health in thalassemia patients. Alloimmunization is one of the important side effects of the injection of these patients. It is the response of the immune system to foreign red blood cell antigens and is therefore called an alloantibody. It occurs following transfusion, pregnancy, and transplantation. In patients who are transfused regularly such as thalassemia and sickle cell anemia patients the frequency of alloantibody is high (13). The factors responsible for alloimmunization are complex and including at least three major reasons: the RBC antigenic differences between the blood donor and the recipient, the recipient's immune status, and the immunomodulatory effect of the allogeneic blood transfusions on the recipient's immune system (14).

In thalassemia patients, the main cause of the development of red cell alloimmunization is repeated blood transfusion. This can decrease the survival of transfused red blood cells and reduce efficacy of blood transfusion (increased transfusion requirements). The frequency of alloimmunization in patients with repeated transfusions varies in different studies. In thalassemia patients, the alloimmunization frequency is 4–50%, in hemato-oncological patients, 1.9–13% patients are alloimmunized, and in kidney disease patients, the alloimmunization frequency is 1.27–13.1% (15).

Several studies have evaluated the prevalence of alloantibodies in thalassemia patients. According to some studies conducted in Iran, the prevalence of alloantibodies is different in various regions, i.e. 7.4% (Tehran), 5.34% (Fars Province), 18.7% (Southwest of Iran), 2.87% (northeast of Iran), 17.9% (southeast of Iran), 5% (Shiraz), 1.53% (Lorestan), 40% (Mazandaran) (16-23).

In the Azarkivan study, screened 835 thalassemia patients for unexpected RBC alloantibodies and reported an alloimmunization rate of 12.1% (24). In this study, 5.05% of thalassemia patients were alloimmunized to RBC antigens. The most common clinically significant alloantibodies detected in our study were Anti-E, Anti-D, Anti-c in the Rh system, and Anti-K in the kell system. In

another study conducted in 2016, the rate of alloimmunization in Iran was reported to be 10%. In this study, the most alloantibodies were related to Anti-E, Anti-D, and Anti-K (25).

In Alipour study, showed that 13% of injected thalassemia patients in Iran have clinically significant RBC alloantibodies, and anti-D and anti-K antibodies are the most common antibodies (26). In moghaddam study showed that the most common alloantibodies were Anti-E, Anti-D, Anti-E, and Anti-c (27).

One reason for Anti-D alloimmunization may be the transfusion of Rh (D) incompatible blood due to human or technical errors or Rh (D) variants in serologically Rh (D) negative blood units. Transfusion of Rh (D) positive blood units to patients with weak D and partial D may also explain Anti-D immunization (28).

The prevalence of alloimmunization and the type of antibody detected are different in different regions of the country. One of the reasons for the production of alloantibody is the antigenic difference between the donor and the recipient (Tests before the first blood transfusion and phenotype determination), which is mainly attributed to racial-ethnic diversity and genetic effects in response to this antigenic stimulation. The greater the antigenic similarity between the recipient and the donor, the less likely it is to stimulate the immune system. In the present study, considering the racial and ethnic diversity in the population of the province, the difference in the prevalence of alloantibody and the type of antibody in thalassemia patients is quite expected.

Appropriate preventive strategies such as RBC phenotyping for patients before beginning transfusion and using extended RBC donor and recipient matching, specifically for Rh and Kell antigens system, could be implemented to avoid complications in these patients. According to the results of this study and other conducted studies, accurate determination of ABO and Rh antigens, and knowledge of the abundance of alloantibodies can provide this possibility for treatment centers and blood product storage centers to allocate reserves for Special patients with constant need to prepare blood injection, which can significantly reduce alloimmunization in subsequent blood injections in these patients.

Conclusion

Alloimmunization is a common consequence in patients that need persistent blood transfusion (thalassemia patients). Some of these antibodies are clinically significant and may affect the safety of further blood transfusion and cause hemolytic transfusion reaction. Determination of RBCs phenotype donor and recipient before beginning chronic blood transfusion, specifically Kell and Rh blood group antigens (C, c, E, e) and doing a careful cross match with evaluating the blood group of a donated unit may help reduce the alloimmunization rate and delayed haemolytic transfusion reactions and enhancing the lifespan in chronic transfusion patients.

Acknowledgement

We sincerely thank the colleagues of the immunohematology department of the Central Headquarters of the Blood Transfusion Organization who helped us in this study.

Ethical statement

The study was approved by the Ethics Committee of the Golestan University of Medical Sciences, Iran (Code: IR.GOUMS.REC.1402.375).

Funding sources

This study did not receive any grants from funding agencies, whether public, commercial, or non-profit.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Author contributions

All authors contributed to one or more aspects of the study.

Data availability statement

All data generated or analyzed during this study are published in this article.

References

- 1) Sahu A, Parida P, Mahapatra S, Sahoo BB. Detection of red cell alloantibodies in thalassaemia patients. *Int J Contemp Pediatr*. 2020 Feb; 7 (2):419-423.
- 2) Fergus N. An overview of thalassemia for parent adopting international health and medicine. Available at: www.comeunity.com/adoption/health/thalassemia.html. Html. 2002.
- 3) Sarookhani MR, Ahmadi MH. Rare and unexpected beta thalassemic mutations in Qazvin province of Iran. *African Journal of Biotechnology*. 2010; 9:95-101.
- 4) Najmabadi H, Teimorian S, Khatibi T, Neishabory M, Pourfarzad F. Amplification refractory mutation system (ARMS) AND reverse hybridization in the detection of beta thalassemia mutation. *Haematologica*. 2002; 87: 1114-16.
- 5) Derakhshandeh-Peykar P, Akhavan-Niaki H, Tamaddoni A, et al. Distribution of beta-thalassemia mutations in the northern provinces of Iran. *Hemoglobin*. 2007; 31:351-356.
- 6) Van Buren NL, Gorlin JB, Corby SM, Cassidy S, FritchLilla S, Nelson SC, et al. How do I incorporate red cell genotyping to improve chronic transfusion therapy? *Transfusion*. 2020; 60(1): 16-25.
- 7) Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. *Blood Cells Mol Dis*. 2006; 37(1):12-20.
- 8) Vaziri M, JavadzadehShahshahani H, Moghaddam M, et al. Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd. *Iran J Ped Hematol Oncol*. 2015; 5(2):93-9.
- 9) Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. *Vox Sang*. 2000; 79(3):129-37.
- 10) Ye Z, Zhang D, Boral L, Liz C, May J. Comparison of blood group molecular genotyping to traditional serological phenotyping in patients with chronic or recent blood transfusion. *J B M*. 2016; 4(03):1-8.
- 11) Dunbar NM, Szczepiorkowski ZM. How do we utilize a transfusion safety officer? *Transfus*. 2015; 55(9):2064-8.
- 12) Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood*. 2000; 96(10):3369-73.
- 13) Keikhaei B, Hiran Far A, Abolghasemi H, et al. Red Blood Cell Alloimmunization in Patients with Thalassemia Major and Intermediate in Southwest Iran. *Iranian Journal of Blood and Cancer*. 2013; 6:41-46.
- 14) Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood*. 2000 Nov 15; 96(10):3369-73.

- 15) Das SS, Biswas RN, Safi M, Zaman RU. Alloimmunization to erythrocyte antigens in patients receiving multiple blood transfusions: Clinico-immunohematological and demographic risk factors and impact of extended red cell phenotyping. *Glob J Transfus Med.* 2021; 6 :171-7.
- 16) Shamsian BS, Arzanian MT, Shamshiri AR, Alavi S, Khojasteh O. Frequency of red cell alloimmunization in patients with-major thalassemia in an Iranian Referral Hospital. *Iran J Pediatr.* 2008; 18:149-53.
- 17) Karimi M, Nikrooz P, Kashef S, Jamalians N, Davatolhagh Z. RBC alloimmunization in blood transfusion-dependent betathalassemia patients in southern Iran. *Int J Lab Hematol.* 2007; 29: 321-6.
- 18) Keikhaei B, Hirad Far A, Abolghasemi H, Mousakhani H, Ghanavat M, Moghadam M, et al. Red blood cell alloimmunization in patients with thalassemia major and intermediate in southwest Iran. *IJ BC.* 2013; 6:41-6
- 19) Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, et al. Alloimmunization among transfusion-dependent thalassemia patients. *Asian J Transfus Sci.* 2009; 3 (2):95-99.
- 20) Amin M, Gholamhossein T, Majid N, Marziyeh H, Narges S, Akbar D, et al. Prevalence of alloimmunization against RBC antigens in thalassemia major patients in south east of Iran. *J Blood Disorders Transf.* 2013; 4:1-4
- 21) Ghorbani Ali-Abadi E, Tavassoli A, Gharehbaghian A, Kasraian L, Khademi R, Taleie A. Evaluation of frequency and specificity of RBC alloantibodies in Namazi Hospital patients in Shiraz, 2010. *Sci J Iranian Blood Trans Organ.* 2013; 10 (3):1-9.
- 22) Kiani A, Abdi J, Shirkhani Y, Kashi M. Prevalence of alloimmunization against RBC antigens in thalassemia major patients of Lorestan province in 2004. *Sci J Iran Blood Transfus Organ.* 2006; 3(3): 265-71.
- 23) Kosaryan M, Mahdavi MR, Roshan P, Hojjati MT. Prevalence of alloimmunisation in patients with beta thalassemia major. *Blood Transfus.* 2012; 10:396-7.
- 24) Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, et al. Blood transfusion and alloimmunization in patients with thalassemia: Multicenter study. *Pediatr Hematol Oncol.* 2011; 28:479-85.
- 25) Darvishi P, Azami M, Sayehmiri K, Sayehmiri F, Goodarzi A, Azarkeivan A, et al. Red blood cell alloimmunization in Iranian beta thalassemia patients: a systematic review and meta-analysis. *ISBT Science Series.* 2016; 11(3):163-73.
- 26) Rostamian H, Javandoost E, Mohammadian M, Alipour A. Prevalence and specificity of red blood cell alloantibodies and autoantibodies in transfused Iranian β -thalassemia patients: A systematic review and meta-analysis. *Asian J Transfus Sci.* 2022; 16:111-20.
- 27) Shaiegan M, Moghaddam M, Mahtab Maghsudlu M, et al. Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients. *IJHOSCR.* 2022; 16(1):9-13.
- 28) Dean L. Blood groups and red cell antigens. Bethesda (MD): National Center for Biotechnology Information (US); 2005.

Table 1. Prevalence of alloantibodies in patients

Alloantibodies	Frequency (n)	Percentage (%)
Anti-K	1	16.7
Anti-c	1	16.7
Anti-E	2	33.3
Anti-D	2	33.3
Total	6	100

Table 2. Clinical and laboratory characteristics of alloantibody-positive thalassemia patients

Sex	Age (Year)	ABO	Rh	Splenectomy	Autoantibody	Alloantibody
Male	44	O	Pos	No	No	Anti-E & Anti-c
Female	36	B	Neg	No	No	Anti-D & Anti-K
Female	22	A	Neg	No	No	Anti-D
Male	34	B	Pos	No	No	Anti-E
Female	43	O	Neg	No	No	Anti-E

Pos: Positive; Neg: Negative